Intracranial cavernous angiomas (CAs) are hamartomatous vascular malformations consisting of thin-walled vascular channels located within the brain, but typically lacking intervening neural parenchyma, large feeding arteries, or draining veins. The CAs occurring in the ventricular system are rare, with an incidence of 2.5% to 10.3% of the intracranial CAs, and those arising from the trigone of the lateral ventricle are even rarer. Till now, there are <20 patients with trigonal CAs have been reported in the English literature. In this study, the authors describe an extremely rare case of multiple intracranial CAs with a trigonal CA mimicking glioma. Furthermore, they also discuss the characteristic aspects of symptoms, radiologic findings, diagnosis, and treatment of this benign lesion.

The successful clinical management of spinal cord injury (SCI) is still a unmet medical need. Despite advances in novel therapeutics, the multifactorial etiology of SCI still poses significant challenge to the mankind. Thus, in the present study, we intend to scrutinize the protective effect of Boldine (BOL), an alkaloid obtained from the boldo tree against experimental spinal cord injury. The effect of BOL was investigated on locomotor function of rats with various biomarkers of oxidative stress (MDA, SOD and GSH), inflammation (TNF-α, IL-1β and IL-6), and apoptosis. Results suggest that BOL showed improvement in locomotor function (on BBB scale) of rats with does-dependent reduction in oxidative stress and inflammation. It also reduces neuronal apoptosis in flow cytometry experiment. The study successfully demonstrated the possible clinical utility of BOL against SCI.

Parkinson’s syndrome (PD) is the second-most common neurodegenerative disease in the world. The chronic disability of PD and the long-term medication required to treat it imposes a huge economic burden on patients and society. Thus, enhancing the therapeutic effect of PD drugs while reducing the side effects caused by long-term drug use has become a challenge that researchers need to overcome. In this study, a compound drug—levodopa/carboxymethyl chitosan/resveratrol nanoparticles (LDP/CMCS/RVT NPs)—with both sustained release and neuroprotective effects was constructed based on carboxymethyl chitosan. The new LDP compound nano-drug can significantly promote glutathione levels of and superoxide dismutase in the substantia nigra and striatum of mice, while increasing the expression of the brain-derived neurotrophic factor. Based on these findings, LDP/CMCS/RVT NPs is expected to provide a new therapeutic strategy for the recovery of midbrain dopamine deficiency and neuroinflammatory changes in PD patients.